Abbreviations & Acronyms AE = adverse event AUC = area under the concentrationtime curve CI = confidence interval C max = maximum observed concentration CR = complete response DLT = dose-limiting toxicity ECOG = Eastern Cooperative Oncology Group FGF = fibroblast growth factor FGFR = fibroblast growth factor receptor ILD = interstitial lung disease INR = international normalized ratio mTOR = mammalian target of rapamycin ORR = objective response rate PD = progressive disease PFS = progression-free survival PK = pharmacokinetic PPES = palmar-plantar erythrodysesthesia PR = partial response RCC = renal cell carcinoma RECIST = Response Evaluation Criteria in Solid Tumor SD = stable disease t max = time at which the highest drug concentration occurs ULN = upper limit of normal VEGF = vascular endothelial growth factor VEGFR = vascular endothelial growth factor receptor Objectives: To assess the tolerability, safety, pharmacokinetics and antitumor activities of lenvatinib, an oral inhibitor of multiple receptor tyrosine kinases, in combination with everolimus, an inhibitor of mammalian target of rapamycin, in Japanese patients with advanced or metastatic renal cell carcinoma after disease progression with vascular endothelial growth factor-targeted therapy. Methods: Lenvatinib 18 mg and everolimus 5 mg once daily were administered on 28-day continuous cycles until disease progression or unacceptable toxicity. Adverse events were evaluated according to the Common Terminology Criteria for Adverse Events version 4.03, and tumor response was assessed according to the Response Evaluation Criteria in Solid Tumor version 1.1. Pharmacokinetics sampling was carried out during the first cycle. Results: Seven patients with clear cell renal cell carcinoma received this combination treatment. Dose-limiting toxicity was not observed. The most commonly observed adverse events were thrombocytopenia and decreased appetite (100%), followed by hypertriglyceridaemia and palmar-plantar erythrodysesthesia syndrome (86%). The most common grade 3 adverse event was lymphopenia (43%). No grade 4 or 5 adverse events occurred. The steady-state mean areas under the concentration-time curves of lenvatinib and everolimus were 3220 and 401 ngÁh/mL, respectively. Five patients (71%) had partial response, and one (14%) had stable disease. Conclusions: Lenvatinib 18 mg and everolimus 5 mg once daily are well tolerated and manageable, and their combined administration has no significant effect on either drug's pharmacokinetics. Overall, this combination therapy shows encouraging antitumor activity in Japanese patients with renal cell carcinoma.
Introduction
RCC is the most common type of kidney cancer and accounts for 90% of total kidney cancer. 1 Increased understanding of the underlying pathogenesis and molecular biology of metastatic or advanced RCC has led to treatment options, including antiangiogenic drugs targeting VEGF and VEGFRs, mTOR inhibitors, and immune checkpoint inhibitors in advanced RCC. 1 Although many treatments are available for patients with advanced RCC, complete and durable tumor responses have not been achieved in the majority of patients, probably because of intratumor heterogeneity and diverse mechanisms of drug resistance leading to tumor growth. [2] [3] [4] [5] [6] [7] [8] Thus, the development of new agents and combination therapies to improve clinical outcome is warranted.
Lenvatinib is an oral inhibitor of multiple receptor tyrosine kinases of VEGFRs (VEGFR1, VEGFR2 and VEGFR3), FGFRs (FGFR1, FGFR2, FGFR3 and FGFR4), platelet-derived growth factor receptor a, ret proto-oncogene, and v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog and has anti-angiogenesis and antitumor activity. 9, 10 On the basis of results from a randomized phase 3 study, lenvatinib was approved for the treatment of radioiodine-refractory differentiated thyroid cancer in the USA and European Union, and for the treatment of unresectable thyroid cancer in Japan. 11 Lenvatinib in combination with everolimus, an inhibitor of mTOR, is expected to enhance anti-angiogenesis and antitumor activity by inhibiting VEGFR, FGFR and mTOR signaling pathways. 12 The randomized phase 2 clinical trial carried out in the USA and Europe showed lenvatinib plus everolimus (18 and 5 mg/day, respectively) significantly prolonged PFS with acceptable and tolerable toxicities relative to that of everolimus (10 mg/day) alone (median 14.6 months vs 5.5 months, hazard ratio 0.40, 95% CI 0.24-0.68) in patients with advanced RCC after one prior VEGF-targeted therapy. 13 This combination regimen was approved for the treatment of patients with advanced RCC after one prior anti-angiogenic therapy in the USA and one prior VEGF-targeted therapy in Europe.
There have been no clinical trials of this combination regimen in Japanese patients. Therefore, we carried out a phase 1 clinical study of lenvatinib in combination with everolimus in Japanese patients with unresectable advanced or metastatic RCC to investigate its tolerability, PK and antitumor activities.
Methods Patients
Patients aged ≥20 years with a histologically or cytologically confirmed diagnosis and evidence of advanced or metastatic RCC, disease progression after VEGF-targeted therapy, and an ECOG performance status of 0-1 were eligible for the study. Patients were required to have adequate organ function as follows: hemoglobin ≥9.0 g/dL; neutrophil count ≥1.5 9 10 3 / lL; platelets ≥10 9 10 4 /lL; total bilirubin ≤1.5 9 ULN; alkaline phosphatase, aspartate aminotransferase and alanine aminotransferase ≤3 9 ULN (≤5 9 ULN for patients with liver metastasis); creatinine clearance ≥40 mL/min; INR ≤1.5; and adequately controlled blood pressure defined as blood pressure ≤150/90 mmHg. A washout period was required from the end of prior treatment to the start of study treatment (other anticancer investigational drugs or antibody therapy: ≥4 weeks; anticancer drugs except for small-molecule targeted drugs, surgical therapy, radiation therapy: ≥3 weeks; endocrine therapy, immunotherapy, small-molecule targeted drug: ≥2 weeks; blood transfusion, blood products, hematopoietic growth factors, including granulocyte colony-stimulating factor preparations: ≥2 weeks). Patients with untreated or unstable metastases to the central nervous system, urine protein ≥1 g/24 h, significant cardiovascular impairment, bleeding or thrombotic disorders or use of anticoagulants requiring therapeutic INR monitoring, active hemoptysis, active infections that require systemic treatment, history of interstitial pneumonia, positive for human immunodeficiency virus or hepatitis B or C virus, uncontrolled diabetes (fasting glucose >1.5 9 ULN), fasting total cholesterol >7.75 mmol/L, or fasting triglyceride levels >2.5 9 ULN were excluded.
The present study was carried out in accordance with the World Medical Association Declaration of Helsinki and Good Clinical Practice Guidelines, and was approved by the institutional review board of each medical institution in Japan. All patients provided written, informed consent before study entry.
Study design
The present phase 1 study aimed to assess the tolerability, safety, PK and antitumor activities of lenvatinib in combination with everolimus in Japanese patients with advanced or metastatic RCC (ClinicalTrials.gov identifier, NCT02454478). Lenvatinib and everolimus were taken orally at the same time once a day in continuous 28-day cycles. The starting doses were 18 mg for lenvatinib and 5 mg for everolimus, which were the same as the approved doses and schedule for advanced RCC in the USA and Europe. Enrollment of six patients was planned to assess DLT during cycle 1. Enrollment interruption was planned if DLT was observed in two or more patients. If a patient failed to receive ≥75% of the planned dose during cycle 1 for a reason other than treatment-related toxicity, the patient was not included in the DLT analysis and an additional patient was to be added as a replacement. If the dosage of lenvatinib 18 mg plus everolimus 5 mg was not tolerable such that more than one-third of patients experienced DLTs during cycle 1 or unacceptable toxicities that were unmanageable with dose interruption and/ or reduction observed until cycle 2, an additional lower-dose cohort (lenvatinib 14 mg and everolimus 5 mg, once daily administration) was considered. In cycle 1, lenvatinib and everolimus were taken orally in the fasting state in the morning, followed by 1 h fasting. In cycle 2 or later, lenvatinib and everolimus were taken consistently either before or after a meal. Treatment was continued until disease progression, development of unacceptable toxicity or withdrawal of consent. The planned doses for dose reduction were 14, 10, and 8 mg for lenvatinib and 5 mg every other day for everolimus.
Study assessment
Safety assessment consisted of monitoring and recording all AEs and serious AEs including periodic laboratory tests, vital signs, 12-lead electrocardiograms, echocardiograms or multiple gated acquisition scans including left ventricular ejection fraction, ECOG performance status and physical examination. AEs were graded according to the National Cancer Institute Common Terminology Criteria for AEs version 4.03, and classified into standardized medical terminology by using the Medical Dictionary for Regulatory Activities version 20.0 (Maintenance and Support Services Organization, McLean, VA, USA). DLT was evaluated to determine the tolerability of lenvatinib in combination with everolimus. DLTs were defined either as failure to administer ≥75% of the planned dosage of lenvatinib or everolimus because of treatment-related toxicity or grade 4 neutropenia lasting >7 days, grade 3 febrile neutropenia, grade ≥3 thrombocytopenia lasting >7 days or requiring blood transfusion, grade ≥3 non-hematological toxicities lasting >7 days (except clinically insignificant or transient abnormal laboratory findings and toxicities manageable with maximal supportive therapy), hypertension uncontrolled by antihypertensive medication, or any thromboembolic event.
For PK evaluation, serial blood samples were collected at predose, and 1, 2, 4, 8 and 24 h after the first dose on day 1 of cycle 1; and at predose, and 1, 2, 4, 8 and 24 h after repeated dose on day 15 of cycle 1. By using non-compartmental analysis methods, plasma concentrations of lenvatinib and whole-blood concentrations of everolimus were calculated to determine the PK parameters, including C max , t max and AUC, at the first and repeated administrations.
Tumor assessment was carried out by investigators using RECIST version 1.1 at screening, every 8 weeks after the study treatment was initiated, and as clinically indicated. Efficacy was evaluated by best overall response consisting of CR, PR, SD, PD and not evaluable. SD had to be achieved at ≥7 weeks after the first dose. CR and PR did not have to be confirmed by assessment at ≥4 weeks. PFS was defined as the time from the date of first dose to the date of first documented PD or death, which ever occurred first. PFS was estimated by using the Kaplan-Meier method.
Results

Patient characteristics
Seven patients were enrolled in the present study from July 2015 to May 2017 in Japan. Baseline patient characteristics are shown in Table 1 . The median age was 66 years (range 59-74 years). Most patients were men (86%), and ECOG performance status was either 0 (71%) or 1 (29%). All patients had clear cell RCC with metastatic sites and previous VEGF-targeted therapy. Six patients had two or more VEGFtargeted therapies. Patients received a median of 11 cycles (range 1-23), and five (71%) patients received ≥10 cycles. The median relative dose intensity was 57.8% (range 46.1-100%) for lenvatinib and 81.4% (range 50.5-100%) for everolimus. Five patients discontinued the study treatment because of disease progression, one patient because of withdrawal of consent and another patient because of a scheduled nephrectomy without disease progression.
Safety and tolerability
No DLTs were observed in six patients. One patient was excluded from DLT analysis because of early discontinuation. This 60-year-old male patient discontinued the study treatment because his general condition became aggravated due to disease progression. The last dosing day of the study treatment was day 7 of cycle 1. The patient with lung, liver, lymph nodes and brain metastases had undergone radical nephrectomy, radiotherapy to brain metastasis and three systemic VEGF-targeted therapies before receiving the study treatment.
The most commonly observed treatment-emergent AEs were thrombocytopenia and decreased appetite (100%), followed by hypertriglyceridemia and PPES syndrome (86% ;  Tables 2 and S1 ). The most common grade 3 AE was lymphopenia (43%), followed by decreased appetite, hypertriglyceridemia, hypophosphatemia and hyponatremia (29%). No grade 4 or 5 AEs were observed. Four non-fatal serious AEs were reported in three patients (cancer pain, spinal column stenosis, and both decreased appetite and dehydration in each patient). Decreased appetite was considered to be related to lenvatinib and not to everolimus by the investigators. Dehydration was considered to be related to both drugs. AEs leading to dose reduction were reported in 86% of total patients for lenvatinib and 43% for everolimus. The events that led to dose reduction in two or more patients were decreased appetite (57%) and fatigue (29%) for lenvatinib, and hypertriglyceridaemia (29%) for everolimus. AEs leading to dose interruption were reported in all patients for both drugs. The events that led to dose interruption in two or more patients were fatigue, pyrexia, hypertriglyceridemia, and ILD (29%) for lenvatinib and fatigue, decreased appetite (57%), ILD (43%), diarrhea, and pyrexia (29%) for everolimus.
Pharmacokinetics
After the first dose in combination with everolimus, the mean C max of lenvatinib was 289 ng/mL and the median t max was 3.87 h. The mean AUC (0Àt) was 2770 ngÁh/mL. After multiple doses, the mean C ss,max of lenvatinib was 257 ng/mL and the median t ss,max was 3.77 h. The mean AUC (0Àt) was 3220 ngÁh/mL (Table 3) . After the first dose in combination with lenvatinib, the mean C max of everolimus was 39.1 ng/ mL and the median t max was 0.92 h. The mean AUC (0Àt) was 211 ngÁh/mL. After multiple doses, the mean C ss,max of everolimus was 41.5 ng/mL and the median t ss,max was 0.97 h. The mean value of AUC (0Àt) was 401 ngÁh/mL (Table 3) .
Antitumor activity
Time-course changes from baseline in the sum of diameters for target tumor lesions of the patients are shown in Figure 1 . Tumor shrinkages and durable tumor controls were observed in all but one patient who discontinued the study treatment because of early disease progression. Five (71%) patients had PR, one (14%) had SD and one (14%) had PD as their best overall response. The ORR was 71% (95% CI 29-96). The median PFS was 9.7 months (95% CI 0.3-20.5). The observed radiological response in a patient is shown in Figure 2 .
Discussion
The present study confirmed the tolerability of lenvatinib 18 mg in combination with everolimus 5 mg in Japanese patients with advanced RCC. No patients experienced DLT, and no patients discontinued study treatment because of toxicities. The treatment-related AEs were well managed with supportive medication or dose adjustment. No unexpected AEs were observed. The safety profile of the combination therapy in this study was within the range of the known safety profiles of each agent, and similar to that observed in the phase 1/2 in the USA and Europe. 13, 14 Decreased appetite, hypertriglyceridemia, diarrhea, nausea, hypertension, fatigue, increased blood cholesterol and decreased weight were observed as common AEs in the studies. Although a high incidence of grade 3 diarrhea had been reported in phase 2 in the USA and Europe, diarrhea in the present study was manageable with supportive medication and dose adjustment without developing to grade 3. 13 However, Japanese patients who received the combination therapy had relatively high incidences of PPES and hematological toxicities, such as thrombocytopenia and lymphopenia. A high incidence of PPES in Japanese patients was also observed in several studies of lenvatinib monotherapy. in all patients were quantifiable). ¶AUC (0Às) (the concentrations at 24 h after administration from the obtained concentration were predicted, and the AUCs were calculated). † †n = 5. Data are shown as the mean AE SD. AUC (0Àt) , area under the concentration-time curve from zero time (predose) to time of last quantifiable concentration; AUC (0Às) , area under the concentration-time curve over the dosing interval on multiple dosing; C ss,max , maximum observed concentration in the steady state.
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Hematological toxicities were observed in Japanese patients treated with lenvatinib or everolimus monotherapy. [15] [16] [17] [18] [19] [20] [21] ILD was observed in three patients with interruption of the combination therapy in the present study. The frequency and severity of ILD were reported to be lower in the combination regimen than those in the treatment with everolimus 10 mg/ day. 13 However, ILD tended to occur with high frequency in Japanese patients who received everolimus monotherapy. 18, 19 All patients experienced dose interruption or reduction of this combination therapy because of AEs in the present study. However, most patients could continue to receive this combination therapy for a long period with no treatment discontinuation because of AEs, which indicated that observed toxicities were managed effectively with supportive medication or dose adjustment in the present study.
The PK parameters of lenvatinib and everolimus in the steady state of the present study, a combination study in nonJapanese patients 13 and Japanese monotherapy studies 16, 21 are shown in Table 3 . The dose of lenvatinib in the phase 1 monotherapy study was 24 mg. Therefore, when the C max and AUC of the monotherapy were normalized to those of an 18-mg dose, the average C max and AUC were 389 ng/mL and 3110 ngÁh/mL, respectively. Although the C max of lenvatinib monotherapy was slightly higher than those of other combination studies, the AUCs were similar among all studies. Regarding everolimus, the C max and AUC of monotherapy were slightly higher than those of other combination studies. The C max and AUC were similar between the present study and the combination study in non-Japanese patients. These results suggested no significant PK drug-drug interaction between lenvatinib and everolimus. The PK profiles in Japanese patients were similar to those in non-Japanese patients.
A relatively high ORR (71%) and a long PFS (median 9.7 months) were observed in the present small phase 1 study in Japan, as well as a phase 2 study in the USA and Europe, with an ORR of 43% and a median PFS of 14.6 months. 13 In the present study, all patients had received prior VEGF-targeted therapy, and most patients (86%) two or more VEGFtargeted therapies. VEGF-targeted therapies showed high efficacy for RCC wherein hypoxia-driven genes, including VEGF, are activated because hypoxia-inducible factor accumulates owing to the mutation of the von Hippel-Lindau gene in clear cell RCC. 1 Compensatory activation of FGF signaling is considered as a potential resistance mechanism of VEGF-targeted therapies. 3 Thus, lenvatinib is expected to be an effective potential treatment option for advanced RCC because of its inhibitory activity of VEGFR and FGFR. Indeed, dovitinib, a VEGFR and FGFR inhibitor, showed antitumor activity in patients with RCC who had progressed on previous VEGF-targeted therapies and mTOR inhibitor, but the activity of dovitinib was no better than that of sorafenib. 22 Activation of the phosphoinositide 3-kinase-AKT-mTOR signaling pathway has been implicated to be associated with high-grade tumor and poor prognosis in RCC. 23 Everolimus is an inhibitor of mTOR and has clinical benefit in advanced RCC with prior VEGF-targeted therapies. 24 A preclinical study suggested that simultaneous inhibition of VEGFR, FGFR and mTOR signaling pathways by lenvatinib and everolimus combination resulted in enhanced antitumor activity. 12 In this study, it was considered that lenvatinib in combination with everolimus enhanced the antitumor activity based on the inhibition of VEGF-and FGF-induced angiogenesis by lenvatinib and everolimus, and the direct antitumor activity of everolimus. 12 Recently, metabolic symbiosis between tumor cells was reported as one of the potential resistance mechanisms of VEGF-targeted therapies. [5] [6] [7] Hypoxic tumor cells metabolize glucose and secrete lactate, whereas normoxic vessel-proximal tumor cells import and metabolize the lactate in a process involving mTOR signaling. These insights might explain the enhanced clinical activity of lenvatinib in combination with everolimus. However, a plausible explanation of why the ORR of the present trial was higher than that of the phase 2 study in the USA and Europe was not identified. The current clinical results and the preclinical data suggest that this combination therapy, which is expected to inhibit the VEGFR, FGFR and mTOR signaling pathways simultaneously, might become a therapeutic option that could overcome intratumor heterogeneity and acquired resistance after other VEGFR-targeted therapies.
In conclusion, the combined regimen of lenvatinib 18 mg and everolimus 5 mg once daily was well tolerated and manageable in the present study. Lenvatinib and everolimus had no significant effect on either PK profile. In addition, the combination therapy showed encouraging antitumor activity in Japanese patients. On the basis of these results, further evaluation of the combination therapy is warranted in Japanese patients with advanced RCC. Currently, a global phase 3 trial (ClinicalTrials.gov identifier, NCT02811861) is ongoing to compare the efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib as first-line therapy in patients, also including Japanese patients, with advanced RCC.
